• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Atossa Therapeutics Inc (NQ: ATOS )

    1.490 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.490
    Bid (Size) 1.330 (15)
    Ask (Size) 1.600 (10)
    Prev. Close 1.490
    Today's Range 1.490 - 1.490
    52wk Range 0.5901 - 2.310
    Shares Outstanding 125,785,200
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MicroMarvel - Atossa Therapeutics
    Atossa Therapeutics, a biopharmaceutical company focused on developing medicines in oncology, has a lead program in Phase II clinical trials for breast cancer, and 100% technical buy signals 
    Via Talk Markets
    ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023
    ATOS stock results show that Atossa Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace

    Performance

    YTD
    +59.36%
    +59.36%
    1 Month
    -21.16%
    -21.16%
    3 Month
    +81.00%
    +81.00%
    6 Month
    +129.20%
    +129.20%
    1 Year
    +121.73%
    +121.73%

    More News

    Read More
    Catalyst Countdown: 3 Biotech Stocks With Upcoming News That Could Move the Market
    Via InvestorPlace
    This Drug Developer Is Dedicated To "Transforming The Breast Cancer Paradigm"
    Via Benzinga
    Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers - Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
    Via ACCESSWIRE
    Atossa Therapeutics backing Endoxifen in the fight against breast cancer
    Via News Direct
    Recap: Atossa Therapeutics Q2 Earnings
    Via Benzinga
    Approximately 30% Of Newly Diagnosed Cancers In Women Will Be Breast Cancers – Atossa Therapeutics Has A Promising Drug To Help With Prevention And Treatment
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Breast Cancer-Focused Atossa Therapeutics Can Possibly Change Treatment Paradigm: Analyst
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
    Via Benzinga
    Could Anixa Biosciences (NASDAQ: ANIX) Be Developing The Vaccine To End One Of The Deadliest Types Of Breast Cancer?
    Via Benzinga
    50% Of Women Have Elevated Breast Density, Which Significantly Decreases the Effectiveness of Mammography - Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
    Via ACCESSWIRE
    50% Of Women Have Elevated Breast Density, Which Significantly Decreases The Effectiveness Of Mammography – Atossa Therapeutics Is Looking To Ensure Earlier, Accurate Diagnosis
    Via Benzinga
    3 Penny Stocks to Make Your ‘Get Rich’ Dreams Come True
    Via InvestorPlace
    3 Penny Stocks Set to Pass the $5 Mark Soon
    Via InvestorPlace
    3 Penny Stocks That Could Skyrocket in the Next 12 Months
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
    Via InvestorPlace
    7 High-Potential Penny Stocks in the Biotech Sector
    Via InvestorPlace
    3 Best Penny Stocks Under $1 to Buy in April
    Via InvestorPlace
    The 3 Best Biotech Stocks Under $1 to Buy for April
    Via InvestorPlace
    The 3 Best Biotech Stocks Under $1 to Buy for January
    Via InvestorPlace
    Stocks That Hit 52-Week Lows On Monday
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.